Research programme: monoclonal antibodies - YZY Biopharma
Latest Information Update: 18 Dec 2015
At a glance
- Originator YZY Biopharma
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Dec 2015 Preclinical trials in Cancer in China (Parenteral)